



Toxicological Profile for Dinitrophenols

August 2021



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
August 2021	Final toxicological profile released
May 2019	Draft for public comment toxicological profile released
March 2011	Addendum to the toxicological profile released
August 1995	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Jennifer Przybyla, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Heather Carlson-Lynch, M.S., D.A.B.T.

Julie M. Klotzbach, Ph.D.

Jenny S. Crisman, B.S.

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

PEER REVIEWERS

1. Martin D. Brand, Ph.D., Buck Institute for Research on Aging (previous affiliation: University of Cambridge), Novato, California
2. David Janz, Ph.D., Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, Saskatoon, Saskatchewan, Canada
3. David M. Wood, MD, FBPhS, Medical Toxicology Office, Guy's Hospital, London, United Kingdom

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	2
1.3 MINIMAL RISK LEVELS (MRLs)	6
CHAPTER 2. HEALTH EFFECTS	9
2.1 INTRODUCTION	9
2.2 DEATH	43
2.3 BODY WEIGHT	51
2.4 RESPIRATORY	54
2.5 CARDIOVASCULAR	55
2.6 GASTROINTESTINAL	57
2.7 HEMATOLOGICAL	59
2.8 MUSCULOSKELETAL	61
2.9 HEPATIC	62
2.10 RENAL	65
2.11 DERMAL	68
2.12 OCULAR	69
2.13 ENDOCRINE	73
2.14 IMMUNOLOGICAL	74
2.15 NEUROLOGICAL	76
2.16 REPRODUCTIVE	78
2.17 DEVELOPMENTAL	79
2.18 OTHER NONCANCER	80
2.18.1 Metabolic Effects from Uncoupling of Oxidative Phosphorylation	80
2.18.2 Mechanism of Action—Oxidative Phosphorylation Uncoupling	84
2.18.3 Effects on Hearing	87
2.19 CANCER	87
2.20 GENOTOXICITY	88
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	98
3.1 TOXICOKINETICS	98
3.1.1 Absorption	98
3.1.2 Distribution	99
3.1.3 Metabolism	101
3.1.4 Excretion	105
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	107
3.1.6 Animal-to-Human Extrapolations	107

3.2	CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE...	108
3.2.1	Increased Susceptibility due to Age	109
3.2.2	Pre-existing Conditions that Increase Susceptibility	109
3.2.3	Factors Increasing Susceptibility to Cataracts.....	110
3.3	BIOMARKERS OF EXPOSURE AND EFFECT	111
3.3.1	Biomarkers of Exposure.....	112
3.3.2	Biomarkers of Effect	113
3.4	INTERACTIONS WITH OTHER CHEMICALS	113
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		116
4.1	CHEMICAL IDENTITY	116
4.2	PHYSICAL AND CHEMICAL PROPERTIES	116
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE.....		121
5.1	OVERVIEW	121
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	123
5.2.1	Production	123
5.2.2	Import/Export.....	124
5.2.3	Use	124
5.2.4	Disposal.....	125
5.3	RELEASES TO THE ENVIRONMENT	125
5.3.1	Air	126
5.3.2	Water.....	127
5.3.3	Soil	128
5.4	ENVIRONMENTAL FATE	128
5.4.1	Transport and Partitioning.....	128
5.4.2	Transformation and Degradation	131
5.5	LEVELS IN THE ENVIRONMENT.....	134
5.5.1	Air	135
5.5.2	Water.....	135
5.5.3	Sediment and Soil	136
5.5.4	Other Media	136
5.6	GENERAL POPULATION EXPOSURE.....	137
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	138
CHAPTER 6. ADEQUACY OF THE DATABASE.....		139
6.1	Information on Health Effects.....	139
6.2	Identification of Data Needs	139
6.3	Ongoing Studies	146
CHAPTER 7. REGULATIONS AND GUIDELINES		147
CHAPTER 8. REFERENCES		149
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS.....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR DINTROPHENOLS	B-1
APPENDIX C.	USER'S GUIDE	C-1
APPENDIX D.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E.	GLOSSARY	E-1
APPENDIX F.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

1-1. Health Effects Found in Humans and Animals Following Oral Exposure to 2,4-Dinitrophenol	3
1-2. Summary of Sensitive Targets of 2,4-Dinitrophenol – Oral.....	7
2-1. Overview of the Number of Studies Examining 2,4-Dinitrophenol Health Effects	12
2-2. Levels of Significant Exposure to 2,4-Dinitrophenol – Oral.....	35
3-1. Nitro Reduction of 2,4-Dinitrophenol	103
5-1. Number of NPL Sites with Dinitrophenol Contamination	121
6-1. Summary of Existing Health Effects Studies on 2,4-Dinitrophenol By Route and Endpoint	140

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 2,4-Dinitrophenol	8
2-1. Levels of Significant Exposure to 2,4-Dinitrophenol – Oral	13
2-2. Levels of Significant Exposure to 2,4-Dinitrophenol – Dermal	42
2-3. Case Reports of Human Fatalities After Oral Exposure to 2,4-Dinitrophenol	44
2-4. Mortality in Laboratory Animals Given a Single Gavage Dose of 2,4-Dinitrophenol	47
2-5. Temperature Dependence of Intraperitoneal LD ₅₀ Values in Mice	51
2-6. Genotoxicity of 2,4-Dinitrophenol <i>In Vivo</i>	89
2-7. Genotoxicity of Dinitrophenols <i>In Vitro</i>	89
2-8. Genotoxicity of Dinitrophenol Metabolites <i>In Vivo</i>	94
2-9. Genotoxicity of Dinitrophenol Metabolites <i>In Vitro</i>	95
4-1. Chemical Identity of Isomers of Dinitrophenols	117
4-2. Physical and Chemical Properties of Dinitrophenols	118
5-1. Facilities that Produce, Process, or Use 2,4-Dinitrophenol	123
5-2. Releases to the Environment from Facilities that Produce, Process, or Use 2,4-Dinitrophenol	126
5-3. Lowest Limit of Detection Based on Standards	134
5-4. 2,4-Dinitrophenol Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	135
7-1. Regulations and Guidelines Applicable to Dinitrophenols	147